ascopubs.org

Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer

Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study PD-1 immune checkpoint ...
ascopubs.org

A phase II study of fruquintinib plus sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results.

PD-1 inhibitor (sintilimab) and fruquintinib plus SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a single-arm, ...
Nasdaq

ProKidney Corp. Reports Positive Topline Results from Phase 2 REGEN-007 Trial of Rilparencel for Chronic Kidney Disease and Plans Submission to ASN 2025 Kidney Week

ProKidney Corp. announced positive topline results from its Phase 2 REGEN-007 trial of rilparencel in patients with chronic kidney disease (CKD) and diabetes, indicating significant improvement in ...